Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 31;19(1):2215149.
doi: 10.1080/21645515.2023.2215149.

Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

Tatenda Yemeke  1 , Hui-Han Chen  1 , Sachiko Ozawa  1   2
Affiliations
Review

Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

Tatenda Yemeke et al. Hum Vaccin Immunother. .

Abstract

Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs. Vaccines can contribute to combating antimicrobial resistance by reducing the incidence of resistant disease cases and lowering overall antibiotic use. Greater utilization and investments in vaccines as a tool for combating AMR might be hampered by limited economic evidence demonstrating the AMR-related value of vaccines. We reviewed the existing literature to assess the state of evidence. We found two modeling studies that provided estimates of AMR-related costs averted by pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness. We did not find any cost-effectiveness studies that directly examined the cost-effectiveness of vaccines in slowing the development of AMR. Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.

Keywords: AMR; Vaccines; antimicrobial resistance; cost-effectiveness; economics.

PubMed Disclaimer

Conflict of interest statement

HC was awarded the Bristol Myers Squibb-University of North Carolina Worldwide Health Economics and Outcomes Research pre-doctoral fellowship. SO has received research funding from the Merck Investigator Studies Program.

References

    1. World Health Organization . Antimicrobial resistance. Geneva, Switzerland: WHO; 2022. [accessed 2022 Dec 15]. https://www.who.int/health-topics/antimicrobial-resistance
    1. World Health Organization . Antimicrobial resistance. Geneva, Switzerland: WHO; 2021. [accessed 2022 Dec 15]. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
    1. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–5. doi: 10.2147/IDR.S234610. - DOI - PMC - PubMed
    1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S0140-6736(21)02724-0. - DOI - PMC - PubMed
    1. Jansen KU, Anderson AS.. The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccines Immunother. 2018;14(9):2142–9. doi: 10.1080/21645515.2018.1476814. - DOI - PMC - PubMed

Substances